Ewan Phillips, Deltex Medical’s Chief Executive LON:DEMG, commented: “We are encouraged that we have been able to secure capital funding for our ODM monitors from major customers in both the USA and UK at a time of restricted capital budgets. The US sales contract means we can now move forward with supporting implementation of ODM in one of the most presitigious of the US platform accounts we announced in 2016.”
Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), has told DirectorsTalk that it has received confirmation of monitor orders worth over GBP0.2m which, as indicated in the trading update announced on 18 January 2017 had moved into 2017 due to the rescheduling of capital allocations in a small number of hospitals.
The largest value sales contract is from the USA for six monitors from a seven hospital system in the Company’s Great Lakes sales territory. The customer had originally planned to start implementation of ODM within its flagship hospital from April 2016 but, following delays in its procurement processes, has now decided to start implementation simultaneously in two additional hospitals.
The other major order is for 13 monitors from a consortium of NHS hospitals in the UK, comprising replacements for nine previously purchased monitors and four additional units.
